Biochemically recurrent prostate cancer (BCR) is the main indication to perform prostate-
specific membrane antigen PET/CT. However, localizing BCR with prostate-specific …

Purpose Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in
patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 (168 …

Our objective was to investigate the factors predicting scan positivity and disease location in
patients with biochemical recurrence (BCR) of prostate cancer (PCa) after primary local …

18 F-DCFPyL is a promising PET radiopharmaceutical targeting prostate specific membrane
antigen (PSMA). We present our experience in this single academic center prospective …

18F-DCFPyL (2-(3-{1-carboxy-5-[(6-18F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-
pentanedioic acid) is a promising PET radiopharmaceutical targeting prostate-specific …

Purpose: Current FDA-approved imaging modalities are inadequate for localizing prostate
cancer biochemical recurrence (BCR). 18F-DCFPyL is a highly selective, small-molecule …

Rationale and Objectives To analyze variables that can predict the positivity of 18 F-DCFPyL-
positron emission tomography/computed tomography (PET/CT) and extent of disease in …

Our objective was to investigate the lesion detection rate of 18F-DCFPyL PET/CT, a prostate-
specific membrane antigen (PSMA)–targeted PET agent, in patients with biochemically …

Aim To investigate the diagnostic performance of early acquisition compared to late imaging
for the detection of local recurrence of prostate cancer by means of 18 F-FCH PET/CT …

Background: Prostate-specific membrane antigen (PSMA)-targeted 2-(3-{1-carboxy-5-[(6-
[18F] fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (18F-DCFPyL) …